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portunity to conduct confirma-
tory analyses before publication 
of an article, thereby advancing 
the ICMJE’s stated goal of in-
creasing “confidence and trust in 
the conclusions drawn from clin-
ical trials.” Finally, persons who 
were not involved in an investiga-
tor-initiated trial but want access 
to the data should financially 
compensate the original investi-
gators for their efforts and invest-
ments in the trial and the costs 
of making the data available.
The writing committee of the Internation-
al Consortium of Investigators for Fairness 
in Trial Data Sharing included P.J. Devereaux, 
M.D., Ph.D., Gordon Guyatt, M.D., Hertzel 
Gerstein, M.D., Stuart Connolly, M.D., and 
Salim Yusuf, M.B., B.S., D.Phil. — all from 
McMaster University, Hamilton, ON, Canada. 
This article was reviewed and endorsed by 
282 investigators in 33 countries, who are 
listed in the Supplementary Appendix.
Disclosure forms provided by the authors 
are available at NEJM.org.
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Participants in clinical research volunteer in order to support 
the development of scientific 
knowledge and help future pa-
tients. Inherent in their commit-
ment is the belief that research 
will lead to new insights that will 
be disseminated. As clinical re-
searchers, we fully support the 
concept of data sharing as fun-
damental to achieving this goal.
We formed the Academic Re-
search Organization Consortium 
for Continuing Evaluation of Sci-
entific Studies — Cardiovascular 
(ACCESS CV) to provide avenues 
for sharing data from cardiovas-
cular clinical trials while mini-
mizing risks and unintended 
consequences. The goal of the 
consortium is to create a strategy 
to thoughtfully operationalize the 
recommendations of the Interna-
tional Committee of Medical Jour-
nal Editors (ICMJE) and the In-
stitute of Medicine (IOM) for 
sharing clinical trial data.1,2 The 
ACCESS CV partners broadly sup-
port the concepts of data trans-
parency and open access. The 
benefits of sharing patient-level 
data from clinical trials include 
confirmation of results, opportu-
nities for new discoveries from 
secondary analyses, and eventu-
ally the possibility of aggregation 
of data sets from related studies 
to facilitate high-quality system-
atic meta-analyses.
The potential benefits of shar-
ing patient-level data need to be 
balanced against potentially un-
intended consequences (see the 
Supplementary Appendix, avail-
able with the full text of this ar-
ticle at NEJM.org). We have iden-
tified the following challenges: 
complexity of the data and meta-
data, publication bias or selection 
bias in proposed new analyses, 
increased risk of type I error 
(from multiple unplanned second-
ary analyses), and patient privacy.
Clinical trial databases are 
commonly large and complex, of-
ten containing millions of data 
points from various sources (e.g., 
case-report forms, central labora-
tory review, safety reporting, and 
end-point adjudication). Attempts 
to validate trial findings made by 
persons who are either unfamil-
iar with the data set structure or 
inexperienced in the analysis tech-
niques could create apparent dis-
crepancies where none exist, po-
tentially alarming the public and 
hindering rather than advancing 
science. The problem may be com-
pounded by publication bias, which 
may lead to undue focus on find-
ings that seem to differ from 
those of the original analysis.
In addition, data sharing could 
lead to a large number of un-
restricted and non–hypothesis-
driven supplementary data analy-
ses, which would increase the 
risk of finding false associations 
(type I errors). Unplanned explor-
atory analyses from a publicly 
shared database may be numer-
ous and redundant. The lack of 
adjustment for multiple testing 
and the absence of prespecified 
hypotheses and transparent ana-
lytic plans could result in spuri-
ous findings, which might ob-
scure the real evidence.
Another potential hazard of 
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sharing individual-patient–level 
data is loss of patient privacy. 
Most patients in a deidentified 
database can be identified on the 
basis of their birth date, sex, and 
ZIP Code.3 Those with rare dis-
eases and the very elderly are at 
an even higher risk of identifica-
tion and privacy violation.
We propose a secure method 
of sharing sensitive patient data 
that balances the legitimate de-
sire of the scientific community 
for data access with the respon-
sibility to ensure high-quality 
analyses and protection of pa-
tients’ expectation of privacy.
First, with regard to gover-
nance of access to trial data, we 
propose that after publication of 
the primary results of a trial, re-
searchers who were not involved 
with the trial design or conduct 
may send requests for analyses 
to the trial’s publications com-
mittee. Beginning 24 months af-
ter publication, analysis requests 
should be considered by a learned 
review group comprising ACCESS 
CV members who were not in-
volved in the trial, along with the 
trial’s principal investigator, a 
trial statistician, and a member 
of the data and safety monitor-
ing board. The 24-month period 
was chosen to allow time to 
build secure access to the data-
base and to allow trial investiga-
tors to perform their own pre-
planned secondary analyses. The 
group’s responsibility would be 
to review all proposals and ap-
prove those that are feasible, 
hypothesis-based, nonduplicative, 
and guided by investigators with 
technical capability and a plan 
for publication. All requests and 
subsequent decisions would be 
posted on an ACCESS CV Web 
portal, ideally within 60 days.
Second, we contend that it is 
critical to facilitate access in an 
orderly manner to support the 
best science and minimize pa-
tient risk. We envision the fol-
lowing elements of a mechanism 
of access to ensure a systematic 
approach: standardized requests 
on a Web portal, disclosure of 
conflicts of interest and publica-
tion plans, adherence to data-use 
agreements for planned analyses, 
provision of appropriate ethics ap-
proval, performance of all analy-
ses using a secure Web link with 
an accompanying audit trail, and 
notification about submission for 
publication.
Such a process would avert the 
problem of multiple groups pro-
posing the same analysis and 
would require investigators to 
have prespecified analysis plans. 
The ICMJE and the IOM3 have 
stated that data-sharing plans 
should be provided at the time of 
trial registration and that the re-
sults from a clinical trial should 
be published in a timely fashion, 
with individual patient data avail-
able 6 months after publication. 
The IOM recommends full data-
base access for secondary analy-
ses beginning 18 months after 
trial completion. (For our specific 
responses to these recommen-
dations, see the Supplementary 
Appendix, available at NEJM.org.)
We propose the following: 
ACCESS CV members would post 
data-sharing plans, following the 
ACCESS CV proposal, on Clinical-
Trials.gov. Briefly, starting at the 
time of publication of primary 
trial results, secondary-analysis 
requests from researchers not 
involved in the trial would be 
submitted to the trial publica-
tions committee. When needed, 
ACCESS CV would provide a 
mechanism for validating the pri-
mary results using the individual 
patient data underlying the pri-
mary publication of a clinical 
trial, no later than 12 months 
after publication. Starting 24 
months after the publication of 
primary results, requests for data 
access for secondary analyses 
would be promptly reviewed by a 
learned review group, as described 
above. ACCESS CV plans to build 
a Web-based portal that allows 
for the public posting of all data 
requests and the subsequent de-
cisions of the independent review 
panel.
An unresolved issue is the ques-
tion of how to provide meaning-
ful academic credit (typically 
authorship) to the team that de-
signed and conducted the trial, 
given that trials are usually enor-
mous undertakings requiring sev-
eral years of work. During the 
review of proposals for second-
ary analyses, we would expect 
trial leaders and people request-
ing access to data to consider 
and discuss this important issue 
and to reach consensus on a path 
forward for each analysis.
ACCESS CV recognizes that to 
achieve these goals, adequate re-
sources and funding are required. 
Since that significant matter has 
not been addressed, we plan to 
work with sponsors of clinical 
trials, the IOM, the ICMJE, gov-
ernmental bodies, and regulatory 
authorities to develop the infra-
structure for the data-sharing 
proposal we describe.
ACCESS CV fully supports 
transparency and open data shar-
ing. We propose these mecha-
nisms for structured data access 
in an effort to provide ready ac-
cess to trial data in a timely 
manner while minimizing risks 
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and barriers. We believe that 
 ACCESS CV is well positioned to 
generate and share clinical trial 
data and, eventually, to develop 
aggregate data sets in cardio-
vascular medicine (see the Sup-
plementary Appendix). The cur-
rent proposal, though specific 
to cardiovascular clinical trials, 
may apply equally to other dis-
ciplines in which groups may 
consider building consortia and 
similar strategies. We aim to in-
crease the utilization of shared 
data as compared with ongoing 
open-access efforts.4,5 We be-
lieve our plans are aligned with 
the IOM’s recommendations and 
with the ICMJE proposal and 
that they will ultimately max-
imize the impact of clinical 
 trials on human health around 
the world.
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A. John Camm, M.D., Keith A.A. Fox, M.B., 
Ch.B., Robert A. Harrington, M.D., William 
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M.B., B.S., Ph.D., Vlado Perkovic, M.B., 
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M.D., M.H.S., Marc S. Sabatine, M.D., M.P.H., 
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The institutional affiliations of the part-
ners and the full list of ACCESS CV partici-
pants are provided in the Supplementary 
Appendix, available at NEJM.org.
Disclosure forms provided by the authors 
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